Related Experiment Video
Updated: Feb 14, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Apigetrin inhibits gastric cancer progression through inducing apoptosis and regulating ROS-modulated STAT3/JAK2
Qian Sun1, Na-Na Lu2, Lei Feng3
1Pharmacy Intravenous Admixture Service Centre, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Abstract:
Apigetrin (APG), as a flavonoid, has many cellular bioactivities, including regulation of oxidative stress, and induction of apoptosis. However, the means by which APG suppresses human gastric cancer are still little to be understood. In the present study, the anti-cancer effects of APG on human gastric cancer cells were investigated. The results indicated that APG could suppress the proliferation and induce apoptosis in gastric cancer cells. Its role in apoptosis induction was through reducing Bcl-2, and enhancing Bax, Caspase-9/-3 and poly ADP-ribose polymerase (PARP) cleavage. In addition, APG incubation resulted in the generation of intracellular reactive oxygen species (ROS) in cells. Meanwhile, APG suppressed constitutive and interleukin-6 (IL-6)-stimulated signal transducer and activator of transcription 3 (STAT3), Janus kinase 2 gene (JAK2) and Src activation. However, ROS scavenger, N-acety-l-cysteine (NAC), diminished apoptosis induced by APG. And APG-triggered de-phosphorylation of STAT3/JAK2 was rescued by NAC pre-treatment. In vivo, APG administration significantly inhibited the gastric cancer cell xenograft tumorigenesis through inducing apoptosis and inhibiting STAT3/JAK2 pathways. Taken together, the findings above illustrated that APG might be used as a promising candidate against human gastric cancer progression.
Insights
Apigetrin (APG), a flavonoid, suppresses human gastric cancer by inducing apoptosis and inhibiting key signaling pathways like STAT3/JAK2. It generates reactive oxygen species (ROS) to achieve these anti-cancer effects.
Area of Science:
- Molecular Biology
- Oncology
- Natural Product Chemistry
Background:
- Flavonoids exhibit diverse bioactivities, including potential anti-cancer properties.
- Apigetrin (APG) is a flavonoid with known cellular effects, but its mechanism against gastric cancer is unclear.
Purpose of the Study:
- To investigate the anti-cancer effects and underlying mechanisms of Apigetrin (APG) in human gastric cancer cells.
- To explore APG's role in apoptosis induction, reactive oxygen species (ROS) generation, and key signaling pathways.
Main Methods:
- In vitro studies on human gastric cancer cells treated with APG.
- Analysis of apoptosis-related proteins (Bcl-2, Bax, Caspase-9/-3, PARP) and ROS levels.
- Investigation of STAT3, JAK2, and Src signaling pathways, including the effect of ROS scavenger N-acetyl-cysteine (NAC).
- In vivo xenograft mouse models to assess APG's anti-tumor efficacy.
Main Results:
- APG suppressed gastric cancer cell proliferation and induced apoptosis by modulating Bcl-2, Bax, and caspase cleavage.
- APG treatment increased intracellular ROS generation, which was crucial for APG-induced apoptosis.
- APG inhibited constitutive and IL-6-stimulated STAT3, JAK2, and Src activation, a process partially dependent on ROS.
- APG administration significantly inhibited tumor growth in vivo by inducing apoptosis and suppressing the STAT3/JAK2 pathway.
Conclusions:
- Apigetrin (APG) exhibits significant anti-cancer effects against human gastric cancer through apoptosis induction and STAT3/JAK2 pathway inhibition.
- ROS generation plays a critical role in mediating APG's pro-apoptotic and anti-proliferative effects.
- APG demonstrates potential as a therapeutic candidate for human gastric cancer treatment.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Hormonal Regulation
Feedback Inhibition
Negative Regulator Molecules
Apoptosis
GTPases and their Regulation
Large G-proteins,...

